-
FDA approves Ferring’s CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for colonoscopy prep
-The U.S. Food and Drug Administration (FDA) has granted Ferring Pharmaceuticals Inc. approval to market CLENPIQ™ (sodium picosulfate,…
0 -
New Ferring and Aché Laboratórios Farmacêuticos facility opens to optimise drug delivery using nanotechnology
-Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo…
-
Ferring receives Swiss approval for Rekovelle®, the first personalised fertility treatment using an approved dosing algorithm
-Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation…
-
Ferring strengthens growth hormone franchise Zomacton® through acquisition of ZomaJet™ needle-free injector device
-Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc…
-
Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer
-Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer…
-
Ferring announces new analysis of Rekovelle® data relating to personalised medicine in fertility patients
-Ferring Pharmaceuticals announced today a new analysis of Rekovelle® (follitropin delta) data that showed cumulative live birth rates were similar…
-
Ferring appoints Lars Peter Brunse to Executive Board
-Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer…
-
Paul Navarre joins Ferring Pharmaceuticals as Chief Executive Officer of Ferring Holding Inc.
-Ferring Pharmaceuticals announced today that Paul Navarre has been appointed Chief Executive Officer of Ferring Holding Inc…
-
Ferring appoints Aaron Graff to Executive Board
-Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer…
-
Ferring commits $10 million to March of Dimes to expand research needed to end preterm birth
-Ferring Pharmaceuticals and the March of Dimes Foundation announced today that Ferring has committed $10 million to support…
PRESS RELEASE 2017
PRESS RELEASE 2017